Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3Thoracic 1Other solid neoplasm 1Breast 1

Conditions

Neoplasms 13Carcinoma, Non-Small-Cell Lung 8Melanoma 5Breast Neoplasms 5Neoplasm Metastasis 4Lymphoma, Non-Hodgkin 3Lymphoma 3Solid Tumor 2Recurrence 2Lung Neoplasms 2Carcinoma 2Advanced Solid Tumor 2Advanced Malignancies 2cMET-dysregulated Advanced Solid Tumors 1Thyroid Neoplasms 1Synovitis, Pigmented Villonodular 1Solid Tumours 1Solid Tumour 1Solid Tumors, KRAS Mutation 1Solid Tumors 1Solid Tumor, Adult 1Prostatic Neoplasms 1Prostate Cancer Patients 1Pharmacokinetics of MDV3100 1Ovarian Neoplasms 1Neoplasms, Plasma Cell 1Multiple Myeloma 1Multiple Endocrine Neoplasia Type 1 1Mesothelioma, Malignant 1Mesothelioma 1

Interventions

Rituximab 57Cyclophosphamide 56fludarabine 37fludarabine phosphate 31Filgrastim 27Etoposide 22Bortezomib 20Melphalan 19Gemcitabine 19Cytarabine 17Bendamustine Hydrochloride 17Peripheral Blood Stem Cell Transplantation 16Vincristine 15pembrolizumab 14aldesleukin 13Prednisone 13Doxorubicin 12Dexamethasone 12Busulfan 12Whole-Body Irradiation 11Vorinostat 11Tacrolimus 11Sirolimus 11sargramostim 10obinutuzumab 10Lenalidomide 10romidepsin 9Radiotherapy 9Rifampin 8Paclitaxel 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Lymphoma × Midazolam × Clear all
NCT01655225 2022-04-08

A Study of LY3023414 in Participants With Advanced Cancer

Eli Lilly and Company

Phase 1 Completed
156 enrolled
BreastLymphoidOther solid neoplasmThoracic

Mesothelioma, Malignant, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lymphoma, Lymphoma, Non-Hodgkin, Mesothelioma, Neoplasm Metastasis

NCT01209832 2019-03-18

A Tasisulam and Midazolam Drug Interaction Study in Cancer Patients

Eli Lilly and Company

Phase 1 Terminated
11 enrolled 10 charts
Lymphoid

Lymphoma, Neoplasm Metastasis

NCT01026415 2014-12-18

Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35)

Seagen Inc.

Phase 1 Completed
73 enrolled
Lymphoid

Carcinoma, Hematologic Diseases, Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Neoplasms, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡